Barclays PLC Boosts Stock Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

Barclays PLC boosted its position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) by 189.7% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 111,666 shares of the company’s stock after purchasing an additional 73,127 shares during the quarter. Barclays PLC’s holdings in ARS Pharmaceuticals were worth $1,618,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the company. First Turn Management LLC purchased a new stake in ARS Pharmaceuticals in the third quarter valued at about $8,603,000. Jacobs Levy Equity Management Inc. lifted its position in ARS Pharmaceuticals by 78.9% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 653,048 shares of the company’s stock worth $9,469,000 after acquiring an additional 288,021 shares during the period. Miura Global Management LLC purchased a new stake in ARS Pharmaceuticals during the 3rd quarter valued at about $3,915,000. Wexford Capital LP acquired a new position in shares of ARS Pharmaceuticals in the third quarter valued at about $3,601,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of ARS Pharmaceuticals by 766.1% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 234,537 shares of the company’s stock worth $3,401,000 after purchasing an additional 207,456 shares during the last quarter. 68.16% of the stock is owned by hedge funds and other institutional investors.

ARS Pharmaceuticals Stock Down 3.2 %

ARS Pharmaceuticals stock opened at $10.79 on Friday. The firm has a market capitalization of $1.05 billion, a price-to-earnings ratio of -21.16 and a beta of 0.88. ARS Pharmaceuticals, Inc. has a 52-week low of $5.19 and a 52-week high of $18.51. The company has a fifty day simple moving average of $13.91 and a 200-day simple moving average of $12.51.

Insider Activity

In other ARS Pharmaceuticals news, Director Laura Shawver sold 14,772 shares of the company’s stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $13.75, for a total value of $203,115.00. Following the transaction, the director now owns 210,346 shares of the company’s stock, valued at $2,892,257.50. This represents a 6.56 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Sarina Tanimoto sold 100,000 shares of ARS Pharmaceuticals stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $14.88, for a total transaction of $1,488,000.00. Following the sale, the insider now owns 1,298,499 shares of the company’s stock, valued at approximately $19,321,665.12. This represents a 7.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 1,258,058 shares of company stock worth $19,369,686 over the last ninety days. Corporate insiders own 40.10% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently commented on the stock. William Blair raised shares of ARS Pharmaceuticals to a “strong-buy” rating in a report on Friday, August 30th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $30.00 price objective on shares of ARS Pharmaceuticals in a research report on Tuesday, October 8th. Finally, Leerink Partners raised their target price on ARS Pharmaceuticals from $21.00 to $25.00 and gave the company an “outperform” rating in a research report on Friday, September 20th. Four research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $24.00.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.